Literature DB >> 31901719

Maintenance immunosuppression in myasthenia gravis, an update.

John Morren1, Yuebing Li2.   

Abstract

Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive/immunomodulatory treatment. Options for immunosuppression include corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, rituximab, cyclophosphamide, eculizumab, intravenous immunoglobulin, subcutaneous immunoglobulin, plasmapheresis, and thymectomy. The practical aspects of long-term immunosuppressive therapy in MG are critically reviewed in this article. Application of one or more of these specific therapies is guided based on known efficacy, adverse effect profile, particular disease subtype and severity, and patient co-morbidities.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Corticosteroid; Immunosuppression; Intravenous immunoglobulin; Myasthenia gravis; Non-steroid immunosuppressive agent; Plasmapheresis; Thymectomy

Mesh:

Substances:

Year:  2019        PMID: 31901719     DOI: 10.1016/j.jns.2019.116648

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  14 in total

1.  Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores.

Authors:  Hong-Yan Li; Ping Jiang; Yanchen Xie; Bing Liang; Ling Li; Cuiping Zhao; Yao-Xian Yue; Hai-Feng Li
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

2.  Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test.

Authors:  Xu Peng; Xiao-Bi Xie; Hong Tan; Dan Zhang; Bo-Tao Jiang; Jie Liu; Shuang Li; Ya-Rui Chen; Tao-Yang Xie
Journal:  Comput Math Methods Med       Date:  2022-06-30       Impact factor: 2.809

3.  Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis.

Authors:  Ying Du; Chuan Li; Yun-Feng Hao; Chao Zhao; Qi Yan; Dan Yao; Lin Li; Wei Zhang
Journal:  J Neurol       Date:  2022-03-03       Impact factor: 6.682

Review 4.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

5.  Effects of Mitophagy on Regulatory T Cell Function in Patients With Myasthenia Gravis.

Authors:  Na Wang; Jiang Yuan; Md Rezaul Karim; Ping Zhong; Yan-Peng Sun; Hong-Yan Zhang; Yun-Fu Wang
Journal:  Front Neurol       Date:  2020-04-07       Impact factor: 4.003

6.  Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus.

Authors:  Zhuajin Bi; Yayun Cao; Jing Lin; Qing Zhang; Chenchen Liu; Mengcui Gui; Bitao Bu
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

7.  Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis.

Authors:  Shengyao Su; Lin Lei; Zhirong Fan; Shu Zhang; Qi Wen; Jingsi Wang; Yan Lu; Li Di; Min Wang; Hai Chen; Yuwei Da
Journal:  Front Neurol       Date:  2022-02-04       Impact factor: 4.003

8.  Psoriasis and Myasthenia Gravis: A Common Th-17 Pathway.

Authors:  Fouad El Sayed; Mariam Kabbani
Journal:  Cureus       Date:  2022-03-12

9.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

10.  Immunotherapy choice and maintenance for generalized myasthenia gravis in China.

Authors:  Chao Zhang; Bitao Bu; Huan Yang; Lihua Wang; Weibin Liu; Rui-Sheng Duan; Meini Zhang; Pei Zeng; Chen Du; Li Yang; Fu-Dong Shi
Journal:  CNS Neurosci Ther       Date:  2020-10-26       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.